Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Healios KK Ord Shs HLOSF

Healthcare Biotechnology
Healios KK is a Japan-based company mainly engaged in business in the somatic stem cell regenerative medicine field and in the iPSC regenerative medicine field, which involves research, development and manufacture of regenerative medicine products (iPSC regenerative medicines) utilizing technologies related to induced pluripotent stem cells (iPS cells, iPSCs). The somatic stem cell regenerative medicine field develops and markets cell therapy drugs for acute stroke and acute respiratory distress syndrome using MultiStem, a somatic stem cell product for which the Company holds patent and patent licensing rights. The iPSC regenerative medicines include the creation of universal donor cells (UD), next-generation iPSCs that reduce the risk of immune rejection regardless of human leukocyte antigen (HLA) type using gene editing technology.


PINL:HLOSF - Post by User

Healios KK Ord Shs > Market maker is holding the stock back.
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Comment by McLachertyon Nov 02, 2010 2:09am
193 Views
Post# 17643475

RE: Market maker is holding the stock back.

RE: Market maker is holding the stock back.I will wait, Ama's post are usually bang on, and I trust her or his judgement. I don't kow what is better VMS with larger float or HLO right now, but with any announcement I think I would bank on HLO with the low float and proven leadership. No side deals here or playing and I like that as much as anything If there is news you will know it with everyone else. ----------Original Message Posted 11/1/2010 1:17:17 PM---------- What is the reason for holding HLO below .40 cents ??? There must be a reason?? Partnership, takeover, merger , or perhaps options for insiders or other, announcement that is related to the trading average price of the day, for approval by TSX-V. Thin daily volumes and zero promotion by management. (management are sleeping at the wheel of a stock that only has 18 Million out).
 Indeed they have done a good job on HLO's Website. Does anyone have any idea what is the cause for the hold back.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities